←
Michael Gratch39 posts
Michael Gratch avatar

Michael Gratch

@mbgratch

Founder & CEO, Flow Therapy. Building the national platform for Counterpulsation Therapy. The physiological category alongside meds and procedures.

◷ Joined April 2009▧ 5 Photos and videos
Michael Gratch avatar
Michael Gratch@mbgratch·May 19

There’s a gap in cardiology that deserves a brighter light. Millions of symptomatic patients are waiting for a therapy that works alongside their meds and procedures, not after. A real next step, way before the thought of “nothing else.” This is who we built Flow Therapy for.

Dr. Filippo Cademartiri avatar
⟳ Michael Gratch retweeted
Dr. Filippo Cademartiri@FCademartiri·May 27

🫀⚠️ We fix the arteries.
 But what if the problem isn’t just in the lumen of the main coronary arteries? This Lancet study goes straight at a blind spot we all know exists—but rarely quantify. 🧠 The setup 1003 real-world patients undergoing invasive angiography + full physiology (FFR, CFR, IMR) So not theory. 👉 actual coronary physiology in practice 🔍 The uncomfortable finding 👉 Coronary microvascular dysfunction (CMD) in ~16% of patients And not just in “normal coronaries”: - 21.5% WITH obstructive CAD - 9.3% WITHOUT obstructive CAD Translation 👉 Microvascular disease is NOT a niche problem 👉 It is embedded within “classic CAD” 📉 Outcomes (this is where it gets real) At ~2 years: 👉 18.8% events with CMD 👉 10.5% without 👉 HR ~1.9 And here’s the kicker: In patients WITHOUT obstructive CAD: 👉 HR ~3.45 🧠 Translation (again, because this matters) You can have: 👉 “normal” coronaries (by FFR) 👉 no revascularization And still: 👉 a 3x higher risk ⚠️ The paradigm problem Our entire workflow is built around: 👉 stenosis 👉 FFR 👉 revascularization But this paper shows: 👉 fixing epicardial disease does NOT normalize risk 🧬 Why? Because CMD reflects: - microvascular dysfunction - endothelial dysfunction - inflammation - diffuse myocardial injury Not a plumbing problem 👉 a biological one 🧠 My take This paper doesn’t just add information. It exposes a structural limitation: 👉 we are solving the visible part of the disease And missing: 👉 the microcirculation 👉 the diffuse component 👉 the residual risk That is the underlying atherosclerotic/metabolic/inflammatory milieu. ⚡ The real implication If you only measure: 👉 stenosis 👉 FFR You are ignoring: 👉 a major determinant of outcomes 🚨 Bottom line CAD ≠ epicardial stenosis Ischemia ≠ FFR alone 👉 Coronary disease is multi-level 👉 And the microcirculation is not optional Final uncomfortable thought We’ve optimized PCI. We’ve optimized stents. We’ve optimized FFR. But: 👉 we still don’t systematically measure what happens beyond them #Cardiology #CMD #Microcirculation #FFR #CardiacRisk #PrecisionMedicine

Post attachment
Michael Gratch avatar
Michael Gratch@mbgratch·May 27

We say Counterpulsation Therapy now. Modern delivery. Built to bring it back into the conversation, and within reach of the patients who benefit. The therapy hasn’t changed. The difference is how well we understand it, and how access is changing.

Michael Gratch avatar
Michael Gratch@mbgratch·May 27

A note on language. For decades, cardiology has known this therapy as EECP. The evidence base was built under that name, and the clinicians who championed it deserve real credit. But the name carried the confines of an earlier era: limited access, uneven awareness.

Post attachment
Michael Gratch avatar
Michael Gratch@mbgratch·May 20

Walking the Gainesville site today. The next clinic is taking shape. Partnership with Northeast Georgia Health System. Opening this summer. More patients with a real next step. The build continues.

Post attachmentPost attachment
Michael Gratch avatar
Michael Gratch@mbgratch·May 19

If you’re a clinician with patients living in that gap, this account will be a place to follow the work. If you’re a patient or family member still searching for a real next step, there is one. And there’s more to come.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

At Flow Therapy, we’re building the national platform to advance that work. Clinics expanding across Texas, North Carolina, and Georgia. 1,000+ referring cardiologists. A clinical pathway used by service line leaders at major health systems. A patient population being seen.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

The science is present. What remains is operational. Awareness is uneven. Access is regional. Most cardiologists were never trained on where Counterpulsation Therapy fits in the pathway. That’s an implementation problem, not a science problem. That’s what we’re focused on.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

Counterpulsation Therapy fills it. A non-invasive program (also called EECP) that improves coronary perfusion, endothelial function, and functional capacity. Robust clinical evidence. Medicare and most commercial plans cover. The physiological layer of cardiovascular care.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

That’s the gap. Not a lack of effort. Not a lack of expertise. A structural opportunity to enhance results: the right therapy at the right point in the pathway.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

These patients aren’t rare. They’re under-recognized, falling through the cracks. Low energy, limitations on exertion despite excellent care. Ready for a meaningful step forward their current plan doesn’t reach. Naming the gap is the first step to closing it.

Michael Gratch avatar
Michael Gratch@mbgratch·May 19

Cardiac pathways typically offer two answers: medication or procedure. A growing population benefits from a third: • Refractory angina with limited revascularization options • ANOCA and microvascular dysfunction • HFpEF with ischemic burden • HFrEF optimized on GDMT

Flow Therapy avatar
⟳ Michael Gratch retweeted
Flow Therapy@FlowTherapyEECP·16 Nov 2023

Proud to highlight the positive outcomes on patients with microvascular dysfunction at the recent AHA Scientific Session. We appreciate @TCHheart for the great partnership on this project. prnewswire.com/news-releases…